Alzheimer's disease: Attack on amyloid-β protein

Journal name:
Nature
Volume:
537,
Pages:
36–37
Date published:
DOI:
doi:10.1038/537036a
Published online

An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimer's disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50

References

  1. Selkoe, D. J. & Hardy, J. EMBO Mol. Med. 8, 595608 (2016).
  2. Sevigny, J. et al. Nature 537, 5056 (2016).
  3. Haass, C. & Selkoe, D. J. Nature Rev. Mol. Cell Biol. 8, 101112 (2007).
  4. Reiman, E. M. et al. Nature Rev. Neurol. 12, 5661 (2016).
  5. Fleisher, A. S. et al. JAMA Neurol. 72, 316324 (2015).
  6. Yu, J. Y. & Watts, R. J. Neurotherapeutics 10, 459472 (2013).
  7. Sperling, R. A. et al. Alzheimer's Dement. 7, 367385 (2011).

Download references

Author information

Affiliations

  1. Eric M. Reiman is at the Banner Alzheimer's Institute, Phoenix, Arizona 85006 USA.

Competing financial interests

E.M.R. is a principal investigator of the Alzheimer’s Prevention Initiative (API), which is involved in the evaluation of anti-Aβ and other promising Alzheimer’s prevention therapies.

Corresponding author

Correspondence to:

Author details

Additional data